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Abstract
Background: Mean platelet volume (MPV) is a marker of platelet size and activity, and is associated 
with a poor prognosis of cardiovascular disease. Studies have shown a relationship between diabetes 
mellitus (DM) and MPV. This study examined the relationship between admission MPV and 2-year 
cardiac mortality in patients with DM and stable coronary artery disease (SCAD) undergoing elective 
percutaneous coronary intervention (PCI).
Methods: A total of 1389 patients were enrolled and divided into two groups according to MPV as fol-
lows: lower MPV (n = 908, MPV ≤ 10.9 fL) and higher MPV (n = 481, MPV > 10.9 fL).
Results: Body mass index, platelet distribution width, MPV/platelet and glycated hemoglobin (HbA1c) 
levels were significantly higher in the higher MPV group compared with the lower MPV group (all  
p < 0.05). The platelet count was significantly lower in the higher MPV group compared with the lower 
MPV group (p < 0.05). MPV was positively associated with HbA1c and fasting plasma glucose levels 
(r = 0.073 and 0.061, p = 0.007 and 0.023, respectively) in bivariate correlation analysis. The 2-year 
cardiac mortality rate was 0.7%, and was significantly lower in the lower MPV group than in the higher 
MPV group in Kaplan-Meier analysis (p = 0.019). Receiver operating characteristic analysis showed  
a good diagnostic value for MPV at predicting long-term cardiac mortality (area under the curve: 0.735, 
95% confidence interval [CI]: 0.590–0.880, p = 0.01). Elevated MPV was a significant risk factor for 
2-year cardiac mortality (hazard ratio: 2.091, 95% CI: 1.075–4.070, p = 0.030) in multivariable Cox 
regression analysis.
Conclusions: Mean platelet volume is a strong, independent prognostic factor in PCI-treated patients 
with DM and SCAD. (Cardiol J 2019; 26, 2: 138–146)
Key words: diabetes mellitus, stable coronary artery disease, cardiac mortality,  
percutaneous coronary intervention
Introduction
Platelets play an important role in the onset of 
cardiovascular disease [1]. Platelet activation is as-
sociated with death, myocardial infarction (MI), and 
other cardiovascular events [2, 3]. Monitoring the 
function of platelets may help evaluate the severity 
of coronary artery disease (CAD) and prognosis. 
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However, because testing platelet function is 
a time-consuming, costly, and technically challeng-
ing process, it is not widely used. Larger plate-
lets contain more dense granules, express more 
adhesion receptors, and have higher thrombotic 
activity, which can reflect the degree of platelet 
activation [4, 5]. Therefore, platelet volume has 
been proposed as an indicator of platelet reactivity. 
Mean platelet volume (MPV) is a precise measure 
of platelet size, and is reported during a complete 
blood count analysis. This index is cost-effective 
and accessible.
Previous studies have reported a relation-
ship between MPV and diabetes mellitus (DM). 
Platelets of patients with DM are characterized by 
dysregulation of several signaling pathways, result-
ing in increased platelet reactivity [6]. Increased 
platelet size and activity may play a role in the 
observed higher risk for developing ST-segment 
elevation myocardial infarction (STEMI) and worse 
outcomes in patients with DM [7].
Previous studies have examined MPV in the 
development of CAD [3, 8–10]. MPV is an important 
factor for helping predict the prognosis of patients 
with CAD [6, 11–13]. Few studies have examined 
MPV in patients with stable CAD (SCAD) and DM. 
Additionally, the prognostic relevance of DM on 
clinical outcome is less apparent in Asian popula-
tions compared with Western populations [14, 15].
The current study aimed to examine the rela-
tionship between MPV at admission and clinical out-
comes in patients with DM and SCAD undergoing 
elective percutaneous coronary intervention (PCI). 
This study also aimed to evaluate whether this index 
can be used as a marker of long-term prognosis.
Methods
Study population
Patients enrolled were admitted to Fuwai Hos-
pital were diagnosed with SCAD, and underwent 
elective PCI between January 2013 and December 
2013. The study was conducted in accordance with 
the principles contained within the Declaration of 
Helsinki, and the Institutional Review Board of 
Fuwai Hospital approved the study protocol. All 
participants provided written informed consent 
before the intervention.
Laboratory examination  
and procedural details
Venous blood samples were collected at ad-
mission in standardized dipotassium EDTA tubes. 
Samples were tested within 2 h of collection to 
minimize variations due to sample aging. MPV and 
platelets were measured using an automated blood 
counter (Sysmex XN-2000 Hematology System; 
Sysmex Corp., Kobe, Japan). Before the proce-
dure, if patients with elective PCI were not taking 
long-term acetylsalicylic acid and clopidogrel, they 
received a loading dose of clopidogrel (300 mg). 
Coronary angiography and PCI were performed 
using standard protocols and guidelines.
Definitions and endpoints 
Patients were divided into three groups ac-
cording to the MPV value (≤ 10.1 fL, group 1; 
10.1–10.9 fL, group 2; > 10.9 fL, group 3). Groups 
1 and 2 were combined and defined as the lower 
MPV group (≤ 10.9 fL) and group 3 was defined 
as the higher MPV group (> 10.9 fL). DM was 
defined as follows: (a) Pre-existing condition 
diagnosed before admission (patients on insulin, 
oral glucose-lowering drugs, or therapeutic diet); 
and (b) Newly diagnosed DM based on fasting 
plasma glucose (FPG) levels ≥ 7.0 mmol/L or 2-h 
plasma glucose levels ≥ 11.1 mmol/L during an oral 
glucose tolerance test [16]. SCAD was generally 
characterized by episodes of reversible myocardial 
demand/supply mismatch related to ischemia or 
hypoxia usually induced by exercise, emotion, 
or other stresses, but it may have also spontane-
ously occurred. Such episodes of ischemia/hypoxia 
were commonly associated with transient chest 
discomfort (angina pectoris). SCAD also included 
stabilized, often asymptomatic, phases that follow 
acute coronary syndrome (ACS) [17]. Death that 
could not be attributed to a noncardiac etiology was 
considered as cardiac mortality, such as intra-stent 
thrombosis, MI, and sudden death in this cohort.
Follow-up of patients
All patients were scheduled for a 2-year clini-
cal follow-up. Patients were clinically monitored 
for major cardiovascular events. The primary end-
point was cardiac mortality. Follow-up data were 
obtained at 30 days, 6 months, 1 year, and 2 years 
by telephone calls, out-patient follow-ups, or let-
ters. Patients were advised to return for coronary 
angiography if clinically indicated by symptoms or 
documentation of myocardial ischemia.
Statistical analysis 
Continuous variables are presented as mean 
± standard deviation (SD) or median (interquartile 
range) and were compared using the Student t-test 
or Mann-Whitney U test, as appropriate. The Sha-
piro-Wilk test was used to determine whether ran-
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dom samples had a normal distribution. Categorical 
variables are presented as numbers and percent-
ages, and were compared using the c2 test or the 
Fisher exact test. In-hospital and 2-year survival 
was evaluated using the Kaplan-Meier method 
and compared using the log-rank test. Relation-
ships between MPV and variables were estimated 
using the Spearman rank correlation coefficient. 
Receiver operating characteristic (ROC) curves 
were estimated for MPV. ROC analysis was used 
to identify possible cut-offs for predicting 2-year 
cardiac mortality. Clinically important variables 
(age, sex, body mass index, hypertension, hyper-
lipidemia, ejection fraction, estimated glomerular 
filtration rate, high-sensitivity C-reactive protein) 
were entered into multivariate Cox analysis. 
Multivariate analysis was performed to estimate 
hazard ratios (HRs) and 95% confidence intervals 
(95% CIs) for identifying independent predictors 
of 2-year cardiac mortality, while adjusting for po-
tential confounders. A two-tailed p value < 0.05 
was considered statistically significant. Statistical 
analyses were performed using SPSS 23.0 (SPSS 
Inc., College Station, TX).
Results
A total of 1389 consecutive patients were 
enrolled. Follow-up at 2 years was completed for 
1380 (99.4%) patients. 
Patient characteristics and outcomes  
according to MPV level and DM
Baseline characteristics according to MPV 
and DM are shown in Table 1. The higher MPV 
group had a higher body mass index (p = 0.003), 
platelet distribution width (p < 0.001), MPV/PLT 
(p < 0.001), and glycated hemoglobin (HbA1c) 
levels (p = 0.023), but a lower platelet count 
(p < 0.001), compared with the lower MPV group. 
Angiographic characteristics according to MPV are 
shown in Table 2. The higher MPV group had 
a higher SYNTAX score and more often had severe 
CAD (left main stenosis and/or 3-vessel disease) 
compared with the lower MPV group, but these 
differences were not significant. There were no 
significant differences in lesions of the left anterior 
descending, left circumflex coronary, and right 
coronary arteries between the groups.
Effect of high MPV on cardiac  
mortality of patients with DM
Over the 2-year follow-up, 3 of 908 patients 
died in the lower MPV group and 7 of 481 patients 
died in the higher MPV group for cardiac reasons 
(p = 0.038) (Table 3). Among all patients, 7 died of 
stent thrombosis, 1 died of MI, and 2 died of sudden 
cardiac death. The cardiac mortality rate was 0.7%. 
Kaplan-Meier survival analysis showed a higher 
2-year cardiac mortality rate in the higher MPV 
group than in the lower MPV group (p = 0.019) 
(Fig. 1). Cox regression showed that MPV was sig-
nificantly associated with 2-year cardiac mortality 
when analyzed as a continuous variable in the uni-
variate model (HR = 2.090, 95% CI: 1.217–3.589, 
p = 0.008) and multivariate models. Similar find-
ings were observed when MPV was analyzed as 
a binary variable (Table 4).
Patients with DM with or without  
requirement for insulin 
Mean platelet volume was similar in patients 
with DM who required insulin and those who did 
not require insulin (p = 0.853). No significant dif-
ference in cardiac mortality was observed between 
patients with or without insulin (p = 0.986). Cox 
regression analysis showed no significant differ-
ence between patients with or without insulin 
(HR = 0.892, 95% CI: 0.230–3.463, p = 0.869).
ROC analysis 
In patients with DM, ROC analysis showed 
good diagnostic value for MPV at predicting 2-year 
cardiac mortality (area under the curve = 0.735, 
95% CI: 0.590–0.880, p = 0.01) (Fig. 2). The cut-off 
value was 10.65 fL.
Bivariate analysis of MPV, HbA1c, and FPG
Mean platelet volume was significantly posi-
tively correlated with HbA1c (r = 0.073, p = 0.007) 
and FPG levels (r = 0.061, p = 0.023) in bivariate 
analysis (Fig. 3).
Discussion
In this study, the relationship between MPV at 
admission and 2-year cardiac mortality in patients 
with DM and SCAD who underwent elective PCI 
was examined. The present study found that: 
1) The cardiac mortality rate was significantly higher 
in the higher MPV group compared with the lower 
MPV group, 2) MPV was positively correlated with 
HbA1c and FPG levels, although the association 
was weak, and 3) MPV was not associated with the 
extent of CAD. 
Mean platelet volume is influenced by multi-
ple risk factors for CAD, including DM, impaired 
fasting glucose, hyperlipidemia, and metabolic 
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Table 1. Basic characteristics of the study population.
MPV ≤ 10.9 (n = 908) MPV > 10.9 (n = 481) P 
Age [years] 59.2 ± 9.5 58.7 ± 9.4 0.409
Sex (male) 691 (76.1%) 367 (76.3%) 0.934
Weight [kg] 74.2 ± 11.3 76.2 ± 11.6 0.002
BMI [kg/m2] 26.1 ± 3.1 26.7 ± 3.3 0.003
Systolic BP [mmHg] 129.2 ± 16.6 129.9 ± 17.2 0.475
LVEF [%] 63.4 ± 7.5 63.0 ± 6.9 0.329
Past medical history:
Dyslipidemia 698 (76.9%) 340 (70.7%) 0.012
Smoker: 0.615
Active smoker 482 (53.1%) 267 (55.5%)
Previous smoker 15 (1.7%) 6 (1.2%)
Hypertension 621 (68.4%) 337 (70.1%) 0.522
Previous MI 227 (25.0%) 141 (29.3%) 0.083
Previous PCI 290 (31.9%) 135 (28.1%) 0.136
Previous CABG 40 (4.4%) 32 (6.7%) 0.072
Previous CVD 114 (12.6%) 59 (12.3%) 0.877
Laboratory finding:
Platelet count [×109/L] 206.7 ± 50.6 173.5 ± 45.4 < 0.001
MPV/PLT 0.05 ± 0.01 0.07 ± 0.02 < 0.001
Hemoglobin [g/L] 142.1 ± 16.1 143.8 ± 14.5 0.049
Hematocrit [%] 41.4 ± 4.2 42.1 ± 3.9 0.004
WBC [×109/L] 6.72 ± 1.71 6.72 ± 1.77 0.949
RBC [×1012/L] 4.64 ± 0.52 4.69 ± 0.50 0.059
RDW [%] 12.8 ± 0.6 12.8 ± 0.7 0.177
PDW [%] 11.5 ± 1.0 14.8 ± 1.6 < 0.001
FPG [mmol/L] 7.4 ± 2.3 7.6 ± 2.5 0.061
eGFR [mL/min/1.73 m2] 91.9 ± 14.5 91.2 ± 15.8 0.379
HbA1c [%] 7.7 ± 1.3 7.8 ± 1.4 0.023
hsCRP [mg/L] 1.47 (0.77, 3.07) 1.44 (0.73, 3.17) 0.539
BNP [pmol/L] 444 (568, 748) 591 (447, 791) 0.262
ET-1 [pmol/L] 0.29 ± 0.17 0.30 ± 0.15 0.396
Uric acid [mg/dL] 5.52 ± 1.34 5.64 ± 1.45 0.128
TG [mmol/L] 1.47 (1.12, 2.05) 1.56 (1.12, 2.23) 0.076
TC [mmol/L] 3.86 (3.30, 4.64) 3.90 (3.35, 4.72) 0.556
HDL-C [mmol/L] 0.99 (0.84, 1.14) 0.97 (0.81, 1.14) 0.120
LDL-C [mmol/L] 2.20 (1.77, 2.83) 2.24 (1.78, 2.81) 0.876
Concomitant medication in hospital:
Acetylsalicylic acid 901 (99.2%) 475 (98.8%) 0.380
Clopidogrel 896 (98.7%) 476 (99.0%) 0.649
Beta-blocker 849 (93.5%) 439 (91.3%) 0.127
Statins 860 (94.7%) 459 (95.4%) 0.564
Data are presented as number (percentage) for categorical data and mean ± standard deviation) or median (interquartile range) for continuous 
data, depending on distribution of the data. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, 
or use of antihypertensive medication. Dyslipidemia was defined as total cholesterol levels > 5.98 mmol/L, low-density lipoprotein levels  
≥ 2.59 mmol/L, or high-density lipoprotein levels ≤ 1.59 mmol/L. The estimated glomerular filtration rate was calculated using the Chronic  
Kidney Disease Epidemiology Collaboration Study equation. 
BMI — body mass index; BNP — B-type natriuretic peptide; BP — blood pressure; CABG — coronary artery bypass grafting; CVD — cardio-
vascular disease; eGFR — estimated glomerular filtration rate; ET-1 — endothelin-1; FPG — fasting plasma glucose; HbAlc — glycated  
hemoglobin; HDL-C — high-density lipoprotein cholesterol; hs-CRP — high-sensitivity C-reactive protein; LDL-C — low-density lipoprotein 
cholesterol; LVEF — left ventricular ejection fraction; MI — myocardial infarction; MPV — mean platelet volume; PCI — percutaneous  
coronary intervention; PDW — platelet distribution width; RBC — red blood cells; RDW — red cell distribution width; TC — totalcholesterol;  
TG — triglycerides; WBC — white blood cells
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Table 2. Angiographic and procedural characteristics.
MPV ≤ 10.9  
(n = 908)
MPV > 10.9  
(n = 481)
P 
Angiographic features:
Multivessel disease 743 (71.8%) 410 (85.2%) 0.266
LM/trivessel disease 483 (53.2%) 272 (56.5%) 0.232
Artery treated:
LM 21 (2.3%) 16 (3.3%) 0.264
LAD 811 (89.3%) 420 (87.3%) 0.264
LCX 171 (18.8%) 86 (17.9%) 0.663
RCA 168 (18.5%) 117 (24.3%) 0.011
Complex type C lesions 528 (58.1%) 284 (59.0%) 0.865
Lesion length [mm] 32.4 ± 18.6 33.2 ± 17.0 0.445
Vessel diameter [mm] 3.10 ± 0.51 3.11 ± 0.52 0.564
Calcified lesions 540 (59.5%) 269 (55.9%) 0.161
Bifurcation 132 (14.5%) 85 (17.7%) 0.126
Intracoronary thrombus 40 (4.5%) 16 (3.4%) 0.242
Chronic occlusion 179 (19.7%) 92 (19.1%) 0.793
In-stent restenosis 42 (4.6%) 24 (5.0%) 0.525
PMI 12 (1.3%) 3 (0.6%) 0.231
SYNTAX score 13.0 ± 8.3 13.2 ± 7.7 0.541
TIMI flow: 0.807
3 872 (96.0%) 462 (96.0%)
2 11 (1.2%) 6 (1.2%)
1 5 (0.6%) 1 (0.2%)
0 20 (2.2%) 12 (2.5%)
Successful PCI 856 (94.3%) 464 (96.5%) 0.181
Stent implantation 844 (93.0%) 457 (95.0%) 0.134
Data are presented as number (percentage) for categorical data and mean ± standard deviation for continuous data. LAD — left anterior  
descending artery; LCX — left circumflex coronary artery; LM — left main; MPV — mean platelet volume; RCA — right coronary artery;  
PMI — periprocedural myocardial infarction; TIMI — Thrombolysis in Myocardial Infarction
Table 3. Two-year follow-up clinical outcomes.
MPV ≤ 10.9  
(n = 908)
MPV > 10.9  
(n = 481)
P 
All-cause death 10 (1.1%) 9 (1.9%) 0.237
Cardiac mortality 3 (0.3%) 7 (1.5%) 0.038
Myocardial infarction 21 (2.3%) 5 (1.0%) 0.143
Revascularization 82 (9.0%) 47 (9.8%) 0.651
TVR 55 (6.1%) 30 (6.2%) 0.894
TLR 46 (5.1%) 22 (4.6%) 0.686
Stent thrombosis 10 (1.1%) 4 (0.8%) 0.782
Stroke 15 (1.7%) 7 (1.5%) 0.780
Bleeding 59 (6.5%) 32 (6.7%) 0.912
Severe bleeding 4 (0.4%) 0 (0.0%) 0.305
MACE 116 (12.8%) 65 (13.5%) 0.697
Data are presented as number (percentage). MACE — major adverse cardiovascular events; MPV — mean platelet volume; TLR — target lesion 
revascularization; TVR — target vessel revascularization
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syndrome [18–20]. In a study of 1411 patients [10], 
MPV was found to correlate with the frequency 
of DM and baseline glycemia. Shimodaira et al. 
[21] found that in prediabetic and normoglycemic 
patients, MPV was positively correlated with FPG 
levels. Verdoia et al. [22] also observed a similar 
phenomenon in their study of 3414 patients who 
underwent coronary angiography. In this study, it 
was found that MPV was positively correlated with 
HbA1c and FPG levels, but this association was 
weak. A possible reason for this finding may be 
that some other features, such as hypertension and 
other metabolic disorders, in addition to diabetes, 
affected platelet size.
Previous studies on the relationship be-
tween MPV and the severity of CAD in patients 
with DM are inconsistent. Sahin et al. [23] found 
that increased MPV was positively associated 
with the severity of CAD in patients with STEMI 
and DM. Abali et al. [24] reported that a high 
MPV may be an effective marker in determining 
the severity of CAD in patients with DM, and that 
a high MPV level may be associated with CAD 
pathophysiology in patients with DM. However, 
Lekston et al. [6] did not find a relationship be-
tween MPV and the number of diseased coronary 
arteries in patients with STEMI and DM who 
received primary PCI. In the current study, MPV 
in patients with DM who received elective PCI 
was examined. It was found that the incidence 
rate of left main and/or 3-vessel disease and 
SYNTAX score appeared to be higher in the 
Table 4. Association between mean platelet volume and cardiac mortality.
HR 95% CI P
MPV (per 1 fL increment) 2.090 1.217–3.589 0.008
Model 1 2.063 1.218–3.494 0.007
Model 2 2.016 1.051–3.870 0.035
Model 3 2.091 1.075–4.070 0.030
MPV (2 groups) 4.401 1.138–17.017 0.032
Model 1 4.577 1.181–17.737 0.028
Model 2 5.652 1.270–25.146 0.023
Model 3 5.773 1.283–25.981 0.022
Model 1: Adjusted for age, sex, and body mass index.
Model 2: Model 1 + hypertension, hyperlipidemia, and left ventricular ejection fraction.
Model 3: Model 2 + estimated glomerular filtration rate and high-sensitivity C-reactive protein. 
CI — confidence interval; HR — hazard ratio
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Figure 1. Kaplan–Meier curves for cardiac mortality. Cu-
mulative Kaplan-Meier event curves for 2-year cardiac 
mortality were significantly higher in the higher mean 
platelet volume (MPV) group than in the lower MPV group.
Figure 2. Receiver operating characteristic curve of 
mean platelet volume for predicting 2-year cardiac mor-
tality; AUC — area under the curve.
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higher MPV group, but this was not significant. 
Further studies are required to determine the 
relationship between MPV and the severity of 
CAD in patients with DM.
Previous studies have reported that pre-
procedural elevated MPV is associated with the 
incidence of major adverse cardiac events following 
PCI [25]. Most of these studies were conducted in 
patients with ACS. A meta-analysis [26] reported 
that MPV was higher in patients who developed 
cardiovascular events than in non-cardiovascular 
event patients, particularly those with MI and 
death. MPV may be a predictive factor of future 
MI or death in patients with ACS. Lekston et 
al. [6] studied the association between MPV at 
admission and clinical outcomes in patients with 
DM and STEMI. They found that MPV had good 
prognostic value for in-hospital and late mortality. 
In the current study, it was found that MPV had 
good prognostic value for 2-year cardiac mortality 
in patients with DM and SCAD, which is consist-
ent with previous studies. However, Shah et al. 
[27] analyzed MPV in 1512 patients who received 
PCI and did not find any correlation between MPV 
and long-term mortality. A possible reason for this 
lack of findings is that they enrolled diabetic and 
non-diabetic patients. 
The possible mechanisms behind increased 
major cardiovascular events in patients with high 
MPV may be an increase in platelet activity and 
aggregation. Platelet turnover also increases in 
these patients. There is an increased release of 
young, large, and reactive platelets from mega-
karyocytes in bone marrow, which results in an 
increased measurement of MPV. High platelet 
turnover has been reported to be associated with 
soluble P-selectin (a platelet activation marker), 
platelet aggregation [28], and inadequate responses 
to antiplatelet drugs [29, 30]. Platelets in people 
with type 2 DM adhere to the vascular endothelium 
and aggregate more readily than those in healthy 
people. Loss of sensitivity to the normal restraints 
exercised by prostacyclin and nitric oxide gener-
ated by the vascular endothelium is a major defect 
in platelet function. Insulin is a natural antagonist of 
platelet hyperactivity. Insulin sensitizes platelets to 
PGI2 and enhances endothelial generation of PGI2 
and nitric oxide. Defects in the action of insulin 
in DM create a condition of disordered platelet 
activity, which is conducive to macrovascular and 
microvascular events [31].
Limitations of the study
This study has some limitations. First, this 
was an observational, single-center study and was 
thus prone to bias and unintentional confounding. 
Second, we did not assess platelet function at the 
same time. Finally, the cohort only included those 
who underwent elective PCI rather than PCI fol-
lowing ACS. Therefore, the rate of major cardio-
vascular events was lower compared with similar 
previous studies.
Conclusions
Mean platelet volume is a strong, independent 
prognostic factor in PCI-treated patients with DM 
and SCAD.
Figure 3. Correlation analysis. Mean platelet volume (MPV) was positively correlated with glycated hemoglobin 
(HbA1c) levels (A) and MPV was positively correlated with fasting plasma glucose (FPG) levels (B).
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